🇺🇸 FDA
Pipeline program

CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

TAS-120-206

Phase 2 small_molecule active

Quick answer

CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Solid Tumors is a Phase 2 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Taiho Pharma Netherlands B.V.
Indication
Solid Tumors
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials